Gαi1/3 Is a Novel Regulatory Target for RANKL Signal Transduction and Osteoporosis
Advanced Science · 2026
DOI: 10.1002/advs.202510836 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Chaowen Bai und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Second Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Osteoporosis, Signal Transduction, RANK Ligand, GTP-Binding Protein alpha Subunits, Gi-Go. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Gusu health talent plan-special talents C, Gusu health talent plan-research project.
Abstract (Originalsprache)
Osteoporosis, characterized by progressive bone loss and increased fracture risk, is a growing concern as the population ages. Current treatments, though advanced, remain limited, underscoring the necessity for novel therapeutic targets. Recent studies have shown that the immune system plays a key role in osteoporosis, with osteoclasts driving bone resorption. Gαi proteins, critical mediators of immune signaling, are implicated in osteoclastogenesis, but their precise role remains unclear. It is demonstrated that Gαi1/3 was highly expressed in osteoclast precursors and mature osteoclasts, with elevated levels in the bone marrow of osteoporotic patients and ovariectomized (OVX) mice. Conditional knockout of Gαi1/3 in osteoclast precursors mitigates OVX‐induced bone loss, improving bone mass and structure. Gαi1/3‐deficient bone marrow monocytes and macrophages exhibit impaired osteoclast formation and reduced bone resorption. In contrast, overexpression of Gαi1/3 enhances osteoclast differentiation and function. In addition, the 173 Asp residue of Gαi3 is identified as crucial for RANK‐TRAF6 binding during RANKL signaling. Inhibition of Gαi1/3 mimics the protective effects of denosumab, a treatment for osteoporosis, in mice. The findings position Gαi1/3 as a critical regulator of osteoclastogenesis and suggest it as a promising therapeutic target for osteoporosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, The Second Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Endocrinology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
- Institution of Neuroscience, Soochow University, Suzhou, China.
- Shanxi Key Laboratory of Rheumatism Immune Microecology, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, China.
ORCID-Profile: Huajian Shan
Förderung
- National Natural Science Foundation of China
- Gusu health talent plan-special talents C
- Gusu health talent plan-research project
- China National Nuclear Corporation Young talent project; Scientific research project of Jiangsu Provincial Health Commission
- Youth Excellence Talent Program of the Second Affiliated Hospital of Soochow University
- Suzhou Applied Basic Research (Medical and Health) Science and Technology Innovation Project
Zitieren
APA
Bai, C., Zhang, M., Liu, L., Tao, L., Xu, C., Chai, H., Shi, X., Wang, Y., Zhang, X., Chen, Q., Liu, D., Bai, J., She, C., Zhou, X., Cao, C., & Shan, H. (2026). Gαi1/3 Is a Novel Regulatory Target for RANKL Signal Transduction and Osteoporosis. Advanced Science. https://doi.org/10.1002/advs.202510836
Vancouver
Bai C, Zhang M, Liu L, Tao L, Xu C, Chai H, et al. Gαi1/3 Is a Novel Regulatory Target for RANKL Signal Transduction and Osteoporosis. Advanced Science. 2026. doi:10.1002/advs.202510836
BibTeX
@article{Bai2026,
author = {Bai, Chaowen and Zhang, Mingchao and Liu, Le and Tao, Lide and Xu, Chenyang and Chai, Hao and Shi, Xin and Wang, Yin and Zhang, Xiaopei and Chen, Qiong and Liu, Dong and Bai, Jinyu and She, Chang and Zhou, Xiaozhong and Cao, Cong and Shan, Huajian},
title = {Gαi1/3 Is a Novel Regulatory Target for RANKL Signal Transduction and Osteoporosis},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202510836}
}
EUVIMED